rimegepant sulfate hydrate

Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.

Rimegepant (BMS 927711) 是一种有效的降钙素基因相关肽 (CGRP) 受体拮抗剂 (Ki=0.027 nM，IC50=0.14 nM)。Rimegepant 可同时用于偏头痛急性发作治疗及预防性治疗。